CEO Christer Alhberg presents at Redeye Life Science Day 2025
Watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at Redeye Life Science Day December 3.
Read more
In the spotlight
Check out the latest updates from Cinclus Pharma
Cinclus Pharma invites to KOL event
Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive GERD, as well as the potential of Cinclus Pharma’s drug candidate linaprazan glurate. The event will take place on Thursday, 11 December, 15:00–16:00 CET / 09:00–10:00 AM EST.
Read more
Cinclus Pharma’s CEO Christer Ahlberg in an interview with Redeye about the Phase III study and the Q3 report
Redeye has interviewed Cinclus Pharma’s CEO, Christer Ahlberg, about the company’s recently initiated Phase III study with linaprazan glurate and the company’s Q3 report.
Read more